英夫利西单抗联合小剂量甲氨蝶呤治疗10例重度银屑病临床观察
摘要
生物制剂能靶向性阻断T淋巴细胞活化,阻断特异的细胞因子参与免疫反应,在欧美国家已广泛应用于银屑病等免疫介导的炎症性疾病,显示出显著的疗效及良好的安全性。我们采用英夫利西单抗(infliximab)联合甲氨蝶呤(MTX)治疗10例重度银屑病,取得良好效果,报道如下。
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2015年第11期815-816,共2页
Chinese Journal of Dermatology
参考文献10
-
1Sfikakis PP. The first decade of biologic TNF antagonists in clinicalpractice: lessons learned, unresolved issues and future directions[J]. Curr Dir Autoimmun, 2010,11: 180- 210.
-
2Moll JM, Wright V. Psoriatic arthritis[j]. Semin Arthritis Rheum,1973,3( 1):55-78.
-
3Reich K, Nestle FO, Papp K, et al. Infliximab induction andmaintenance therapy for moderate-to-severe psoriasis: a phase III,multicentre, double-blind trial [J]. Lancet, 2005, 366 (9494):1367-1374.
-
4Antoniou C,Stefanaki I,Stratigos A, et al. Infliximab for thetreatment of psoriasis in Greece: 4 years of clinical experience at asingle centre[j]. Br J Dermatol, 2010,162(5): 1117-1123.
-
5Mease P. Infliximab ( Remicade ) in the treatment of psoriaticarthritis[j]. Ther Clin Risk Manag, 2006: 2(4): 389-400.
-
6Arends S, Lebbink HR, Spoorenberg A, et al. The formation ofautoantibodies and antibodies to TNF-a blocking agents in relationto clinical response in patients with ankylosing spondylitis[j]. ClinExp Rheumatol, 2010, 28 ?5): 661-668.
-
7Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signsand symptoms of psoriatic arthritis: results of the IMPACT 2 trial[J]. Ann Rheum Dis, 2005,64(8): 1150-1157.
-
8Motaparthi K, Stanisic V, Van Voorhees AS, et al. From themedical board of the national psoriasis foundation:recommendations for screening for hepatitis B infection prior toinitiating anti-tumor necrosis factor-alfa inhibitors or otherimmunosuppressive agents in patients with psoriasis[j]. J Am AcadDermatol, 2014,70( 1): 178-186.
-
9Wilsmann-Theis D, Fronhoffs K, Ehler LK,et al. Low-dose metho-trexate -a therapeutical kick in TNF-alpha antagonist treatment forrecalcitrant psoriasis vulgaris[j]. Dermatol Ther, 2014,27( 1): 55-59.
-
10刘伦飞,郑敏.英夫利西单抗在银屑病中的应用进展[J].中华皮肤科杂志,2013,46(3):216-219. 被引量:6
二级参考文献27
-
1Kimber I,Cumberbatch M, Dearman RJ, et al. Cytokines andchemokines in the initiation and regulation of epidermal Langer-hans cell mobilization. Br J Dermatol, 2000, 142(3): 401-412.
-
2Pastore S, Gubinelli E, Leoni L, et al. Biological drugs targetingthe immune response in the therapy of psoriasis. Biologies,2008,2(4): 687-697.
-
3Griffiths CE, Barker JN. Pathogenesis and clinical features ofpsoriasis. Lancet, 2007, 370(9583): 263-271.
-
4Pasparakis M, Courtois G, Hafner M, et al. TNF-mediatedinflammatory skin disease in mice with epidermis-specificdeletion of IKK2. Nature, 2002, 417(6891): 861-866.
-
5Raho G, Vena GA, Bizzoca A, et al. Influence of infliximab onkeratinocyte apoptosis in psoriasis patients. ImmunopharmacolImmunotoxicol, 2011, 33(1): 227-231.
-
6Reich K, Nestle FO, Papp K, et al. Infliximab induction andmaintenance therapy for moderate-to-severe psoriasis: a phaseIII, multicentre, double-blind trial. Lancet, 2005,366 (9494):1367-1374.
-
7Menter A, Feldman SR,Weinstein GD, et al. A randomizedcomparison of continuous vs. intermittent infliximab maintenanceregimens over 1 year in the treatment of moderate-to-severeplaque psoriasis. J Am Acad Dermatol, 2007, 56( 1): 31.el-15.
-
8Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment oftumour necrosis factor antagonists in the treatment of psoriasis.Br J Dermatol, 2010, 162(6): 1349-1358.
-
9Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatmentsfor moderate to severe plaque psoriasis: systematic review andmeta-analysis. Dermatology, 2009, 219(3): 209-218.
-
10Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drugsurvival rates for adalimumab, etanercept and infliximab in pa-tients with psoriasis vulgaris. Br J Dermatol, 2011,164(5):1091-1096.
共引文献5
-
1鲁延富,伍斌,李林丽.银屑病中西医治疗研究进展[J].医学综述,2015,21(22):4121-4124. 被引量:21
-
2林宇飞.英夫利西单抗治疗强直性脊柱炎的疗效和安全性评价[J].中外医疗,2016,35(25):109-110. 被引量:1
-
3魏建玲,张波,刘颖,夏焕章.人源化抗人TNFα单克隆抗体纯化工艺的优化[J].沈阳药科大学学报,2017,34(1):79-83. 被引量:5
-
4孙俊波,赵璐,许华,付婷婷.TNF-α单克隆抗体对糖尿病周围神经病变的作用[J].广东医学,2018,39(19):2881-2884. 被引量:5
-
5齐婧,解方,刘卉莹,宋翠豪,李承新.英夫利西单抗治疗中重度银屑病的疗效及安全性研究[J].中国药物应用与监测,2019,16(6):325-327. 被引量:3
-
1张郁,郝建军,王砚宁,边东达,虞瑞尧.检测血清TNF-α对阿维A联合UVB治疗银屑病的疗效评价[J].中国麻风皮肤病杂志,2007,23(11):1024-1025.
-
2徐薇.系统性红斑狼疮血液系统损害[J].现代实用医学,2008,20(11):832-832. 被引量:2
-
3刘明星,贺芳,杨文卿,邓惠群,裴静,陈敦金.妊娠对小鼠肠黏膜免疫系统T淋巴细胞活化的影响[J].中华妇产科杂志,2014,49(1):50-51. 被引量:1
-
4朱爱群,向旭东,张东山.淋巴细胞变化在主动脉夹层中的临床意义[J].中国急救医学,2011,31(5):394-396. 被引量:7
-
5唐琦峰,李琦,钱燕宁,王忠云,季晓辉.围手术期异体输血对胃癌病人CD_4^+T细胞CD_(25)表达的影响[J].济宁医学院学报,2004,27(1):8-10.
-
6刘晓霞,王雪玲,李振红,陈育民,陈剑华.八珍汤对人外周血T淋巴细胞体外增殖和活化的影响[J].生物医学工程学杂志,2010,27(4):855-858. 被引量:7
-
7韦方,周永刚,李安洁,王树辉,袁军.血脂康对急性冠脉综合征患者淋巴细胞亚群的影响[J].贵州医药,2012,36(1):1-3. 被引量:3
-
8翁建宇,杜欣,张建军,陆泽生,吴穗晶,陈运贤,林伟.rhG-CSF对正常供者淋巴细胞亚群及其活化的影响[J].肿瘤防治研究,2004,31(6):333-335.
-
9傅佳萍,蔡真,林茂芳.γ射线辐照对T淋巴细胞增殖及活性影响的实验研究[J].中华血液学杂志,2003,24(8):436-437. 被引量:5
-
10田普训,吴军,李钊伦,薛武军,丁小明,贺伟峰,易绍萱,陈希伟.重组腺病毒介导CD40L和CTLA4Ig的共表达和对人混合淋巴细胞反应的抑制作用[J].中华器官移植杂志,2005,26(11):694-695.